FTC Suit Against Cephalon’s Reverse Settlements Focuses On Side Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency claims that Cephalon's deals with four generic companies constitute unfair competition under the FTC Act.
You may also be interested in...
Patent Settlement Bill Advances - And Firms Fight Back With Examples Of Early Generic Launches That Would Be Prohibited
Four years ago, Teva inked a patent litigation settlement with Wyeth that enabled it to launch generic Effexor XR seven years before the patent on the drug expired
Patent Settlement Bill Advances - And Firms Fight Back With Examples Of Early Generic Launches That Would Be Prohibited
Four years ago, Teva inked a patent litigation settlement with Wyeth that enabled it to launch generic Effexor XR seven years before the patent on the drug expired
Pfizer Stalls Generic Lipitor With Ranbaxy Deal
Settlement could give 20 more months of unchallenged U.S. marketing.